ArticleAntioxidants (Basel, Switzerland)2024
10(E)-Pentadecenoic Acid Inhibits Melanogenesis Partly Through Suppressing the Intracellular MITF/Tyrosinase Axis.
Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Preparation of Glabridin-Loaded Liposomes and Their Inhibition Effects on Melanogenesis.Molecules (Basel, Switzerland) · 2026Article
- Enhancement of Anti-Melanogenic Activity ofMarine drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Melanogenesis, the biological process responsible for melanin synthesis, plays a crucial role in determining skin and hair color, photoprotection, and serving as a biomarker in various diseases. While various factors regulate melanogenesis, the role of fatty acids in this process remains underexplored. This study investigated the anti-melanogenic properties of 10(E)-pentadecenoic acid (10E-PDA) through both in silico and in vitro analyses. SwissSimilarity was utilized to predict the functional properties of 10E-PDA by comparing it with structurally similar lipids known to exhibit anti-melanogenic effects. Subsequent in vitro experiments demonstrated that 10E-PDA significantly reduced melanin production and intracellular tyrosinase activity in α-MSH (melanocyte-stimulating hormone)-stimulated B16F10 melanoma cells without exhibiting significant cytotoxicity at concentrations up to 15 μM. Further mechanistic studies revealed that 10E-PDA inhibited the nuclear translocation of microphthalmia-associated transcription factor (MITF), consistent with the decrease observed in p-MITF protein levels. It also decreased the mRNA levels of tyrosinase-related proteins (TRP-1, TRP-2) and tyrosinase, while reducing the protein levels of TRP-1 and tyrosinase, but not TRP-2. These findings suggest that 10E-PDA exerts its anti-melanogenic effects by modulating the MITF/tyrosinase axis, presenting potential therapeutic implications for skin pigmentation disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.